Spero Therapeutics’ (SPRO) “Buy” Rating Reiterated at HC Wainwright

Spero Therapeutics (NASDAQ:SPRO)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 434.35% from the stock’s current price.

Several other analysts also recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Tuesday, August 6th. TD Cowen upgraded Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th.

Spero Therapeutics Price Performance

Shares of SPRO stock opened at $1.31 on Thursday. Spero Therapeutics has a 1-year low of $0.99 and a 1-year high of $1.89. The stock’s fifty day moving average price is $1.33 and its 200 day moving average price is $1.44. The company has a market cap of $70.73 million, a price-to-earnings ratio of 3.05 and a beta of 0.62.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The business had revenue of $10.20 million for the quarter, compared to the consensus estimate of $9.80 million. Spero Therapeutics had a return on equity of 25.67% and a net margin of 14.74%. During the same quarter in the previous year, the business earned ($0.23) EPS. As a group, equities research analysts anticipate that Spero Therapeutics will post -1.59 earnings per share for the current year.

Institutional Trading of Spero Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SPRO. Virtu Financial LLC purchased a new stake in Spero Therapeutics in the 1st quarter worth approximately $31,000. Acadian Asset Management LLC boosted its position in Spero Therapeutics by 121.8% in the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after purchasing an additional 418,742 shares in the last quarter. Murchinson Ltd. boosted its position in Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after purchasing an additional 11,210 shares in the last quarter. Renaissance Technologies LLC boosted its position in Spero Therapeutics by 14.2% in the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after purchasing an additional 121,492 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in Spero Therapeutics in the 4th quarter worth approximately $1,570,000. 25.60% of the stock is owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.